Everyone's Tracking Menopause. Nobody's Treating It

A billion women, 0.55% of the research, and a wave of apps that route them back to doctors who were never taught to help. The money went to measurement. The answers didn't.

A billion women will be in perimenopause or menopause by 2030. Over the past decade, menopause drew 0.55% of femtech research funding.

That 0.55% is not a bad quarter. It is a ten-year figure, Digital Science's analysis of grant funding across the entire modern femtech era.

So hold two facts next to each other. The category has never been hotter, Apple, Oura, WHOOP, a billion-dollar unicorn in Midi, all moved in over the last eighteen months. And the research base underneath all of it has been sitting near zero the whole time.

The money went to measurement. It did not go to answers. Yet.

Let's start with why the freeze happened in the first place.

On July 9, 2002, the Women's Health Initiative halted the hormone arm of the largest women's health trial ever run, citing raised risks of breast cancer, heart disease, and stroke. In the quarter before, US clinicians wrote 22.4 million hormone therapy prescriptions. Within nine months, prescriptions fell 32%. The FDA added boxed warnings. Pharma pulled promotion. A field went dark.

The verdict was misread. The average woman in that trial was in her sixties, more than a decade past menopause onset. The 2007 reanalysis, led by WHI investigator JoAnn Manson, produced the timing hypothesis: hormone therapy started before 60, or within ten years of onset, carries a materially different risk profile than therapy started at 68. The alarm that froze the category described women who were not the ones seeking treatment.

But the misread is 2002. The question we are all asking is why it is still 2026, and menopause still gets treated as an afterthought.

A generation of doctors trained in the vacuum. Today only 6.8% of family medicine, internal medicine, and OB-GYN residents say they feel adequately prepared to manage menopause. One in five received no menopause lecture at all in residency. As of 2023, 92% of OB-GYN residency programs still had no dedicated menopause curriculum. This is the load-bearing fact of the whole market. The clinicians women are told to see were, by and large, never taught to treat what they came in for.

Now comes the tech, which, yes, we are happy and excited about- finally, some recognition in bio tracking.

But read what the new tools actually promise.

Apple added perimenopause tracking at WWDC 2026, seven years after it launched cycle tracking. Its own product VP framed the value as helping a woman "understand more about what's going on with your body and be better prepared to talk to your doctor." Apple is explicit that it is not a diagnostic tool. Oura and WHOOP added perimenopause features in 2025 with the same framing. The endpoint of nearly every consumer menopause tool is identical: generate a clean record, then hand it to a physician.

Hand it to which physician? The 93% who never felt prepared to manage this?

That is the flaw at the center of the tracking boom, and it is not a knock on any one company. Apple building a good dashboard is Apple doing what Apple is good at. The problem is structural. The measurement layer is being built at consumer speed, cheap, scalable, shippable in an OS update. The solution layer, trained clinicians, reimbursed treatment, drugs, moves at the speed of medicine, which is to say slowly and expensively.

Data is not a diagnosis. A pattern is not a prescription. Handing someone a chart of their own suffering is not the same as treating it. They all know what they are going through; they can feel it. What they want to know is how to get some relief, how to prepare, and how to get through it.

So where are the actual answers coming from? Follow that money, because it moves differently.

Two hormone-free hot-flash drugs have now cleared the FDA on the corrected science: fezolinetant (Veozah, Astellas) in 2023, and elinzanetant (Lynkuet, Bayer) in October 2025, the latter cutting moderate-to-severe symptoms by more than 73% at twelve weeks and cleared even for women in breast cancer treatment. Those are answers. They took two decades and hundreds of millions in trials, and they exist because someone funded the biology, not the dashboard.

On the care side, Midi Health crossed a $1 billion valuation in February 2026 on a model that is boring by design: licensed clinicians, insurance coverage, prescriptions, hormone therapy where appropriate. Its founder's line, women's health was treated "like an afterthought for too long," is the thesis. Midi's own estimate puts untreated menopause symptoms at $25 billion a year in medical cost and lost productivity. Set that beside 0.55% of research funding. The distance between those two numbers is the entire opportunity.

And the demand is now arriving from payroll, not just patients. In 2023, 4% of US employers offered menopause-specific benefits. For 2025, 18% planned to, per Mercer. Menopause got reframed from a wellness nicety into a retention line item, because the women moving through it sit at peak earning years and are the most expensive employees to replace.

The Luteal read, for anyone building or investing and feeling lost in the noise: the menopause market has split into two, and they are not the same business. One tracks. One treats. The tracking layer is already crowded, already commoditized, and mostly ends its value proposition at the clinic door.

The treating layer, clinicians who know the current evidence, reimbursement, drugs, diagnostics that resolve rather than record, is where the underfunding still lives and where the defensibility is.